Author

Karen Tintaya

Observed names: K. Tintaya, Tintaya, Karen

OpenAlex ID: A5049476437

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

2018 · Gustavo E. Velásquez, Meredith B. Brooks, et al. · American Journal of Respiratory and Critical Care Medicine · 116

Development and Validation of a Food Frequency Questionnaire to Estimate Intake among Children and Adolescents in Urban Peru

2017 · Carly Rodriguez, Emily Smith, et al. · Nutrients · 66

PDF

Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study

2017 · S. S. Chiang, S. Roche, et al. · The International Journal of Tuberculosis and Lung Disease · 54

Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis

2017 · C. A. Peloquin, G. E. Velásquez, et al. · Antimicrobial Agents and Chemotherapy · 45

A Cross Sectional Study of Knowledge and Attitudes Towards Tuberculosis amongst Front-Line Tuberculosis Personnel in High Burden Areas of Lima, Peru

2013 · Mark Minnery, Carmen Contreras, et al. · PLoS ONE · 41

PDF

Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts

2016 · Omowunmi Aibana, Xeno Acharya, et al. · PLoS ONE · 31

PDF

Accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening tool in hospitalized patients being evaluated for tuberculosis in Lima, Peru

2024 · Amanda Biewer, Christine Tzelios, et al. · PLOS Global Public Health · 15

Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up

2023 · Sara M Sauer, Carole D Mitnick, et al. · Clinical Infectious Diseases · 9

PDF

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

2023 · C. Zeng, C. D. Mitnick, et al. · The International Journal of Tuberculosis and Lung Disease · 9

FAST tuberculosis transmission control strategy speeds the start of tuberculosis treatment at a general hospital in Lima, Peru

2021 · Dylan B. Tierney, Eli Orvis, et al. · Infection Control and Hospital Epidemiology · 9

PDF

Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis

2026 · Eunsol Yang, Pieter Van Brantegem, et al. · Clinical Infectious Diseases · 2

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial

2025 · Elizabeth Mackay, Gareth Platt, et al. · The Journal of Infectious Diseases · 2

PDF

Diagnostic accuracy of an exhaled breath test for TB in hospitalized patients with cough or risk

2024 · A. Biewer, K. Tintaya, et al. · The International Journal of Tuberculosis and Lung Disease · 2

Erratum for Peloquin et al., “Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis”

2017 · C. A. Peloquin, G. E. Velásquez, et al. · Antimicrobial Agents and Chemotherapy · 2

Microbiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru

2024 · Qi Tan, Chuan-Chin Huang, et al. · International Journal of Infectious Diseases · 1

PDF

Prevalence and clinical implications of Aspergillus infection among tuberculosis patients in Peru

2026 · Alicia E. Madden, Chuan-Chin Huang, et al. · Journal of Infection

PDF

Adaptive bandit algorithms increase efficiency of mobile tuberculosis screening programs

2025 · Jiujia Zhang, Lauren Linde, et al. · Scientific Reports

PDF

A qualitative study of home- versus facility-based TB treatment for adolescents in Lima, Peru

2025 · B. Roman-Sinche, F.M. Doradea, et al. · Public Health Action

Healthcare worker perceptions of the FAST TB infection control strategy

2025 · D.B. Tierney, R.R. Nathavitharana, et al. · Public Health Action

“I have to breathe”: A Mixed-Methods Pilot Study to Assess the Feasibility, Acceptability, Cost, and Effectiveness of an Intervention for Post-Tuberculosis Lung Disease

2024 · Carlos Almeida, Rafael Durand, et al. · Global Journal of Health Science

Reply to te Brake et al. : Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

2019 · Gustavo E. Velásquez, Meredith B. Brooks, et al. · American Journal of Respiratory and Critical Care Medicine

WARMI-SMS: Sending one text to improve two lives: using mobile technologies to improve maternal health in Peru

2016 · O. Paulino, M. DeLeon, et al. · Annals of Global Health

Works count: 23

Citation count: 404

H-index: 9

I10-index: 7